glp-1 dunn nc DietWorks Companion Compounded Semaglutide GLP-1 Care |

Secondary outcomes included nonfatal MI, nonfatal stroke, HHF and renal composite outcome, defined in most trials as a composite of progression to end-stage renal disease or a sustained decrease of at least 40% in estimated glomerular filtration rate (eGFR)

[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy used for weight loss since late April in order to transition patients off compounded drugs, according to the news release

With a 5 mg/mL vial, 1.0 mg = 20 units

In contrast, patients with diabetes may be more accustomed to long-term medication routines, making adherence more stable

Alcohol Consumption Continues to Decline Alcohol consumption among current GLP-1 users is at a record low after months of steady decline, with 47% of GLP-1 users drinking at least one alcoholic beverage per week